This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Moran, L. J. Articles by Norman, R. J. Search for Related Content PubMed PubMed Citation Articles by Moran, L. J. Articles by Norman, R. J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Weight Control Related Collections Female Endocrinology Obesity

The Use of Anti-Müllerian Hormone in Predicting Menstrual Response after Weight Loss in Overweight Women with Polycystic Ovary Syndrome

Research Centre for Reproductive Health (L.J.M., R.J.N.), Discipline of Obstetrics and Gynaecology, University of Adelaide, Adelaide SA 5005, Australia; and Commonwealth Scientific and Industrial Research Organisation Human Nutrition (L.J.M., M.N., P.M.C.), Adelaide 5000, Australia

Address all correspondence and requests for reprints to: Robert Norman, Discipline of Obstetrics and Gynaecology, University of Adelaide, 6th Floor, Medical School North, Adelaide SA 5005, Australia. E-mail: Robert.norman{at}adelaide.edu.au.

Background: Polycystic ovary syndrome (PCOS) is associated with reproductive and metabolic abnormalities, specifically menstrual dysfunction and anovulation in conjunction with elevated pre-antral follicle number and arrested follicular maturation. Although anti-müllerian hormone (AMH), an inhibitor of follicle recruitment and maturation, is increased in women with PCOS, the usefulness of circulating AMH levels as a clinical predictor of menstrual response to weight loss in PCOS is not known.

Methods: Overweight women with PCOS (n = 26, age 32.9 ± 5.8 yr, weight 98.9 ± 20.8 kg, body mass index 36.1 ± 7.0 kg/m², mean ± SD) followed an 8-wk weight loss and 6-month weight maintenance program.

Results: Net reductions in weight (4.6 ± 4.8 kg), waist circumference (6.0 ± 5.3 cm), testosterone (0.3 ± 0.6 nmol/liter), fasting insulin (3.7 ± 7.6 mU/liter), and the homeostasis model assessment of insulin sensitivity (0.7 ± 1.3) occurred for all subjects over the entire study duration. Of 26 subjects, 15 (57.7%) responded to the intervention with improvements in menstrual cyclicity (responders). Compared to nonresponders, responders had lower AMH levels at baseline (23.6 ± 12.0 vs. 37.9 ± 17.8 pmol/liter; P = 0.021). Only responders had reductions in fasting insulin (6.1 ± 5.9 mU/liter; P = 0.001) and homeostasis model assessment (1.3 ± 5.9; P = 0.002) with acute weight loss (wk 0–8). Baseline AMH was most strongly predicted by baseline ghrelin, free testosterone, and insulin (r² = 0.528; P = 0.002).

Conclusions: Overweight women with PCOS who respond to weight loss with menstrual improvements have significantly reduced preweight loss AMH and demonstrate improvements in surrogate measures of insulin resistance with weight loss. Pretreatment AMH is a potential clinical predictor of menstrual improvements with weight loss in PCOS.

This article has been cited by other articles:

				M.-J. Chen, W.-S. Yang, C.-L. Chen, M.-Y. Wu, Y.-S. Yang, and H.-N. Ho The relationship between anti-Mullerian hormone, androgen and insulin resistance on the number of antral follicles in women with polycystic ovary syndrome Hum. Reprod., April 1, 2008; 23(4): 952 - 957. [Abstract] [Full Text] [PDF]